Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 52 year-old gentleman with metastatic pheochromocytoma received single fraction spine stereotactic radiosurgery (SSRS) to an isolated L3 metastasis. Two years later, he developed widespread osseous metastatic disease involving nearly every vertebral body level with the striking exception of the treated L3 vertebrae. The "seed and soil" hypothesis of metastatic dissemination was developed over a century ago and states that tumors cells (the "seed") preferentially grow in select host tissue microenvironments (the "soil"). The high-dose radiation delivered by SSRS may have altered the microenvironment "soil" of the treated L3 vertebrae, rendering it inhospitable to the growth of future metastases. With emerging evidence in support of high-dose stereotactic radiation for oligometastatic disease, there will likely be increasing opportunity to observe and understand treatment changes in the tissue microenvironment and how it relates to the potential for metastatic seeding.
 ...
PMID:Seed, soil, and spine stereotactic radiosurgery: A unique case of metastatic dissemination. 3218 94

Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that originate in endocrine tissues throughout the body. Peptide receptor radionuclide therapy (PRRT) has emerged as a promising therapeutic option for patients with locally advanced and/or metastatic disease refractory to standard of care treatment. The landmark international phase III NETTER-1 trial led to the approval of 177Lu-DOTATATE (Lutathera) in the treatment of somatostatin receptor-positive gastroenteropancreatic NETs. Similarly, data from the multicenter, phase II Study IB12B led to the approval of meta-[131I]Iodo-Benzyl-Guanidine (I31I-MIBG) for treatment of iobenguane scan-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma. With the clinical approval of these novel radiopharmaceuticals for managing select patients with NETs, additional studies are needed to refine patient selection, predict and assess therapy response, and optimize radiopharmaceutical delivery and clinical outcomes.
 ...
PMID:Radiopharmaceuticals for Neuroendocrine Tumors. 3324 37


<< Previous 1 2 3